Short answer
Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on March 2, 2026 reporting Item 8.01 (Other Events). Offering closed Feb 27, 2026; 20,294,117 shares sold including full overallotment exercise at $8.50/share.
Vir Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Offering closed Feb 27, 2026; 20,294,117 shares sold including full overallotment exercise at $8.50/share
- Gross proceeds ~$172.5M before underwriting discounts and offering expenses
- Full exercise of 2,647,058-share overallotment signals strong underwriter demand
- Significant dilution event: ~20.3M new shares issued; net cash impact depends on final fees deducted
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vir Biotechnology, Inc. 8-K filings
Get the next VIR 8-K as it lands
Follow VIR for push alerts, or ask the research agent what this filing means.